CHIN-HSIAO TSENG2020-06-012020-06-0120181262-3636https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023754057&doi=10.1016%2fj.diabet.2017.05.011&partnerID=40&md5=482b0a1902d67a4d5fa1d0aa675ea6dehttps://scholars.lib.ntu.edu.tw/handle/123456789/496057[SDGs]SDG3pioglitazone; 2,4 thiazolidinedione derivative; antidiabetic agent; pioglitazone; age; cancer incidence; cancer patient; cancer risk; chronic obstructive lung disease; diabetic patient; disease duration; drug exposure; hazard ratio; human; ICD-9; Letter; lung cancer; major clinical study; non insulin dependent diabetes mellitus; priority journal; propensity score; sex; Taiwanese; tobacco dependence; case control study; complication; lung tumor; non insulin dependent diabetes mellitus; Taiwan; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Neoplasms; Taiwan; Thiazolidinedionesletter10.1016/j.diabet.2017.05.011286841632-s2.0-85023754057